Effects of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by Composite Physiologic Index (CPI)

被引：0
|
作者：
Nambiar, A. M. [1 ]
Molina-Molina, M. [2 ]
Padilla, M. [3 ]
Song, J. [4 ]
Mueller, H. [5 ]
Stowasser, S. [5 ]
Rohr, K. B. [5 ]
Wells, A. U. [6 ,7 ]
机构：
[1] Univ Texas Hlth San Antonio, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX USA
[2] Univ Hosp Bellvitge, ILD Unit, IDIBELL, Barcelona, Spain
[3] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Pulm & Crit Care Med, Seoul, South Korea
[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[6] Royal Brompton & Harefield NHS Fdn Trust, Natl Inst Hlth Res, Resp Biomed Res Unit, London, England
[7] Imperial Coll, Natl Heart & Lung Inst, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1905
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
    Matteson, Eric
    Kelly, Clive
    Distler, Joerg
    Mann-Vold, Anna Maria Hoff
    Seibold, James
    Mittoo, Shikha
    Distler, Oliver
    Goeldner, Rainer-Georg
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [22] Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial
    Koschel, D.
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S.
    Stowasser, S.
    Coeck, C.
    Goeldner, R. G.
    Clerisme-Beaty, E.
    Schlenker-Herceg, R.
    Brown, K. K.
    PNEUMOLOGIE, 2020, 74 : S106 - S107
  • [23] Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burden
    Bendstrup, E.
    Moua, T.
    Okamoto, M.
    Tomassetti, S.
    Valenzuela, C.
    Wuyts, A.
    Miede, C.
    Lievens, D.
    Bonella, F.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [24] Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
    Makino, Shigeki
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 13 - 19
  • [25] From Bench to Bedside: Nintedanib for Progressive Fibrosing Interstitial Lung Diseases
    Garlick, Kristopher
    Wollin, Lutz
    Distler, Joerg
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 822 - 822
  • [26] FROM BENCH TO BEDSIDE: NINTEDANIB FOR PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES
    Wollin, L.
    Distler, J.
    Redente, E.
    Riches, D.
    Stowasser, S.
    Schlenker-Herceg, R.
    RESPIROLOGY, 2019, 24 : 171 - 171
  • [27] Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
    Flaherty, Kevin R.
    Wells, Athol U.
    Cottin, Vincent
    Devaraj, Anand
    Inoue, Yoshikazu
    Richeldi, Luca
    Walsh, Simon
    Stowasser, Susanne
    Coeck, Carl
    Goeldner, Rainer-Georg
    Clerisme-Beaty, Emmanuelle
    Schlenker-Herceg, Rozsa
    Brown, Kevin K.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [28] THE INBUILD TRIAL OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: SUBGROUP OF ASIAN PATIENTS
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Schlenker-Herceg, Rozsa
    Kolb, Martin
    Brown, Kevin K.
    Quaresma, Manuel
    Kolb, Martin
    Brown, Kevin K.
    RESPIROLOGY, 2019, 24 : 87 - 88
  • [29] Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
    Matteson, Eric
    Antin-Ozerkis, Danielle
    Bonella, Francesco
    Chaudhuri, Nazia
    Cottin, Vincent
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus
    Wuyts, Wim
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 260 - 262
  • [30] Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
    Matteson, Eric
    Distler, Oliver
    Distler, Joerg H. W.
    Kuwana, Masataka
    Pope, Janet
    Seibold, James
    James, Alexandra
    Schlenker-Herceg, Rozsa
    Rohr, Klaus
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345